Media Center
- No
-
Category
- Show all
- Press Release
- News Article
- PR Video
- CEO Story
- Title
- Author
- Time uploaded
- Views
- Likes
- 53
- Press Release
- Press Release PharmAbcine Receives HREC Approval in Australia for the Phase 1a/b Trial of Its Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)
- PharmAbcine
- 18 Sep 2023
- Views2198
- 0
- 52
- Press Release
- Press Release PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD
- PharmAbcine
- 24 May 2023
- Views2945
- 0
- 51
- Press Release
- Press Release PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination with KEYTRUDA® (pembrolizumab)
- PharmAbcine
- 13 Dec 2022
- Views3001
- 0
- 50
- Press Release
- Press Release PharmAbcine to Participate in the 41th Annual J.P. Morgan Healthcare Conference and Biotech Showcase™ 2023 during JPM Week
- PharmAbcine
- 9 Dec 2022
- Views1856
- 0
- 49
- Press Release
- Press Release PharmAbcine to participate in Jefferies 2022 London Healthcare Conference
- PharmAbcine
- 25 Oct 2022
- Views1453
- 0
- 48
- Press Release
- Press Release PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022
- PharmAbcine
- 18 Oct 2022
- Views1684
- 0
- 47
- Press Release
- Press Release PharmAbcine to Participate in BIO-Europe 2022
- PharmAbcine
- 27 Sep 2022
- Views1318
- 0
- 46
- Press Release
- Press Release PharmAbcine Signs MoU with FutureChem to Explore Possibilities of Developing Novel Radiopharmaceuticals
- PharmAbcine
- 1 Sep 2022
- Views1493
- 0
- 45
- Press Release
- Press Release PharmAbcine to participate in Jefferies Global Healthcare Conference and BIO International Convention
- PharmAbcine
- 12 May 2022
- Views2192
- 0
- 44
- Press Release
- Press Release PharmAbcine Announces Positive Results for Its Novel TIE2-Activating Antibody in GLP Toxicology Study
- PharmAbcine
- 27 Apr 2022
- Views2094
- 0